TScan Therapeutics, Inc. (TCRX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

TScan Therapeutics, Inc. (TCRX) closed at USD 0.24 on 2026-10-15, a change of -87.6 % over the past year, with a market capitalization of USD 15.66M.

TScan Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

TScan Therapeutics, Inc. key figures

Previous close

USD 0.24 (2026-10-15)

1-year change

-87.6 %

Market cap

USD 15.66M

Enterprise value

USD 6.39M

P/E ratio (trailing)

-0.25

P/E ratio (forward)

-0.40

EPS (trailing)

-0.91

EPS (forward)

-0.57

PEG ratio

n/a

Price to book

0.23

Revenue growth

-65.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.91

Employees

138

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for TScan Therapeutics, Inc. and compare it with other stocks.